CD-19 CAR-T Cell for Pediatric ALL or Lymphoma

Launched by HONG KONG CHILDREN'S HOSPITAL · Mar 4, 2025

Keywords

ClinConnect Summary

This clinical trial is looking at a new treatment for children with certain types of blood cancers, specifically relapsed or refractory acute lymphoblastic leukemia (ALL) and lymphoma. The treatment involves using the child's own immune cells, known as T cells, which are modified in a lab to better attack cancer cells by targeting a specific protein called CD19. This trial aims to find out how safe this treatment is and how well it works in children who haven't responded to previous therapies.

To participate in the trial, children must be between 1 and 17 years old and have had at least two prior treatments for their cancer, but still have active disease. They also need to have a specific type of cancer that shows the presence of the CD19 protein. Participants can expect to undergo a procedure to collect their T cells, followed by treatment with the modified cells after a short course of chemotherapy to prepare their body. It's important for families to know that they will need to provide informed consent, meaning they must understand the trial details and agree to their child’s participation.

Gender

ALL

Eligibility criteria

• Inclusion Criteria:
• • Subjects must have relapsed or refractory ALL or lymphoma treated with at least two lines of therapy. Disease must have either progressed after the last regimen or presented failure to achieve partial or complete remission with the last regimen.
• • The patient's disease must be CD19 positive, either by immunohistochemistry or flow cytometry analysis on the last biopsy available.
• • Age 1-17 years.
• • Performance status: Subjects \> 10 years of age: Karnofsky ≥ 50%; Subjects ≤ 10 years of age: Lansky scale ≥ 50%.
• • Normal organ function.
• • Total bilirubin ≤ 3 times upper limit of normal
• • AST (SGOT) ≤ 5 times upper limit of normal
• • ALT (SGPT) ≤ 5 times upper limit of normal
• • Serum Creatinine ≤ 2 times upper limit of normal
• • Subjects must have the following hematologic function parameters: Hemoglobin (Hb) level \> 8 g/dL; Absolute Lymphocyte Count \> 0.1x10\^9/L; Platelet \> 50x10\^9/L
• • Prior therapy wash-out. At least 2 weeks or 5 half lives, whichever is shorter, must have elapsed since any prior systemic therapy at the time the subject is planned for leukapheresis.
• • Subjects' parent or legal guardian must have the ability to understand and the willingness to sign a written informed consent document.
• Exclusion Criteria:
• • Autologous transplant within 6 weeks of planned CAR T cell infusion.
• • Recipient of CAR-T cell therapy outside of this protocol.
• • Active central nervous system (CNS) or meningeal involvement by tumor.
• • History of additional active malignancy other than non-melanoma skin cancer, carcinoma in situ (e.g. cervix, bladder, breast).
• • Active human immunodeficiency virus (HIV) infection.
• • Subjects with uncontrolled intercurrent illness including, but not limited to ongoing or active infection, symptomatic congestive heart failure, unstable angina pectoris, cardiac arrhythmia, pulmonary abnormalities or psychiatric illness/social situations that would limit compliance with study requirements.
• • Pregnant or breastfeeding women.
• • Evidence of myelodysplasia or cytogenetic abnormality indicative of myelodysplasia on any bone marrow biopsy prior to initiation of therapy.
• • Serologic status reflecting active hepatitis B or C infection.